SLC5A2 and chronic kidney disease: Of note, similar composite endpoints have been applied in other trials investigating SGLT2 inhibitors, such as the DAPA-CKD, CREDENCE, EMPA-KIDNEY and the EMPEROR-Preserved trials (NCT03057951) [7, 8, 6, 20].